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1. Introduction
Chronic myeloid leukemia is one of the most thoroughly studied and, undoubtedly, best
understood neoplasms. There are about 4000 and 5000 new cases of CML every year in the
USA. CML is a hematologic stem cell malignancy that typically evolves in 3 distinct clinical
stages: chronic and accelerated phases and blast crisis. The chronic phase lasts several years
and is characterized by accumulation of myeloid precursors and mature cells in bone marrow,
peripheral blood, and extramedullary sites. The accelerated phase lasts 4 to 6 months and is
characterized by an increase in disease burden and in the frequency of progenitor/precursor
cells. The blast crisis lasts a few months and is the terminal phase of chronic myelogenous
leukemia, characterized by the rapid expansion of a population of myeloid or lymphoid
differentiation-arrested blast cells (Calabretta and Perrotti 2004; Radich 2007).
The cytogenetic hallmark of CML is the Philadelphia chromosome (Ph). It is a product of a
reciprocal translocation between chromosomes 9 and 22 (t[9;22][q34;q11]). The Bcr-abl
oncogene, responsible for the deregulated tyrosine kinase, arises out of the conjugation
between the breakpoint cluster region gene (Bcr) on chromosome 22 and the Abelson kinase
(Abl) gene on chromosome 9. This oncogene activates multiple signal transduction pathways
such as Ras/Raf/mitogen-activated protein kinase [MAPK], phosphatidylinositol 3 kinase,
STAT5/Janus kinase, and Myc (Fig. 1). The Bcr-Abl tyrosine kinase activity leads to uncon‐
trolled cell proliferation and significantly reduced apoptosis and so starts the malignant
expansion of pluripotent stem cells in the bone marrow. The Wnt/ß-catenin pathway was also
found to be critical for the evolution to blast crisis as far as its activation was observed in
primary cell samples from patients with CML. Most of the pathways activated by Bcr-Abl are
known, but the pathways downstream Bcr-Abl that are critical for oncogenesis and transfor‐
mation are yet not well understood. For example, several transcription factors like Jun B, MZF1
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and δEF1 appear to be involved in CML progression. Jun B has been shown to be down-
regulated in CML progression. The transcription factors MZF1 and δEF1 that play key role in
hematopoietic stem cell differentiation, including modulation of CD34 and cMyb expression,
are also deregulated during CML progression (Calabretta and Perrotti 2004; Steelman, Pohnert
et al. 2004; Jabbour, Cortes et al. 2007; Radich 2007; Druker 2008; Roychowdhury and Talpaz
2011). All these findings reflect the recent knowledge about the molecular disease pathogenesis
and are platform for translating bench research into clinical application of target-driven
therapeutic strategies.
Figure 1. Pathways activated by the fusion oncoprotein Bcr-Abl. The RAS pathway becomes constitutively activated by
mechanisms involving the interaction of Bcr-Abl with the growth factor receptor-binding protein (Grb-2)/Gab2 com‐
plex. This leads to enhanced activity of the guanosine diphosphate/guanosine triphosphate (GDP/GTP) exchange fac‐
tor Sos, which promotes the accumulation of the active GTP-bound form of Ras. Bcr-Abl interacts also indirectly with
the p85 regulatory subunit of PI3K via various docking proteins including GRB-2/Gab2 and c-cbl. Activation of the
PI3K pathway triggers an Akt-dependent cascade that has a critical role in BCR/ABL transformation by regulating the
subcellular localization or activity of several targets such as BAD, MDM2, IκB-kinase α, and members of the Forkhead
family of transcription factors. Another signaling pathway activated by BCR/ABL is that dependent on signal transduc‐
er and activator of transcription 5 (STAT5). The consequence of this activation is inhibition of apoptosis and enhanced
survival.
Treatment of this disease improved dramatically with the development of tyrosine kinase
inhibitors (TKIs). Recently, the modern therapy of CML includes the use of TKIs (first and
second generation), stem cell transplantation and clinical trials with novel agents such as novel
multiple kinase inhibitors, Aurora kinase inhibitors, arsenic trioxide, hystone deacetilase
inhibitors, proteasome inhibitors, other semi-synthetic drugs (Fig. 2). Imatinib is the golden
standard in CML therapy and serves as first-line drug of choice in the chronic phase of CML
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(CP-CML) whereas second generation TKIs are taken in consideration after appearance of
resistance to imatinib due to Bcr-Abl mutations. Accoridning to de Lavallade et al. only 62,7%
of the patients treated with imatinibe achieved complete cytogenetic response (CCyR) and up
to 5% of the patients present with advanced disease are poorly responsive to TKIs in general
(de Lavallade, Apperley et al. 2008; Roychowdhury and Talpaz 2011). In other words, about
one third of CML patients devepole intolerance or resistance to TKIs and therefore they need
alternative therapies.
Figure 2. Clinical algorithm for CML therapy: chronic, accelerated and blast phase (adapted from Roychowdhury et al.,
2011, 25(6): 279-90).
2. Tyrosine-kinase inhibitors
Imatinib, dasatinib and nilotinib are today the three clinically applied tyrosine kinase inhibi‐
tors of the fusion oncoprotein Bcr-BL for the treatment of CML and Ph (+) ALL (Fig. 3, Table
1). The constitutively active Bcr-Abl tyrosine kinase functions by transferring a phosphate
group from ATP to tyrosine residues on various substrates (signaking molecules) to cause
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excess proliferation of myeloid cells typical for CML. Imatinib and the other two tyrosine
kinase-inhibitors block the binding of ATP to Bcr-Abl, thus inhibiting its kinase activity (Fig.
4). They also act on other components of the cellular metabolism and signalling, e.g. Abl and
ARG (Abl-related gene), C-kit receptor (KIT), receptors for platelet growth factor alpha
(PDGFR-α) and beta (PDGFR-β), receptor for colony stimulating factor 1 (c-FMS) etc.
(Kantarjian, Cortes et al. 2010). All tyrosine kinase inhibitors have good gastrointestinal
absorption, which makes them suitable for oral application.
Figure 3. Chemical structures of first and second line tyrosine kinase-inhibitors.
2.1. First generation tyrosine-kinase inhibitors — Imatinib
Imatinib was introduced for clinical use in 1998 for the treatment of CML. It showed high
efficacy and revolutionized the disease management. Nowadays, Imatinib is the first-line drug
of choice for the treatment of patients with CML in chronic phase and Ph (+) ALL as it induces
long lasting remissions and is well tolerated as compared to conventional cytostatics (Fig. 2).
Imatinib stops the progression of CML at early stages (Baccarani and Dreyling 2009).
Imatinib reaches Cmax within 2 to 4 h. Its total bioavailability is 98%. The half-lifes of Imatinib
and its main metabolite, N-demethyl derivative (CGP74588), are 18 h and 40 h, respectively.
Plasma protein binding (mainly albumin and α1-acid glycoprotein) for imatinib reaches 95%.
The drug is primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2D6,
CYP2C9 and CYP2C19. The main active metabolite of Imatinib is one N-demethylated
piperazine derivative, formed by CYP3A4 and has in vitro activity similar to that of Imatinib.
Imatinib is a potent inhibitor of CYP2C9, CYP2D6 and CYP3A4/5, which is described in in
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vitro studies conducted with human liver microsomes. It is eliminated with the faeces, mainly
in the form of respective metabolites. Imatinib clearance in one 50 year-old-patient, weighing
50 kg is 8 L/h, while in patient weighing 100 kg, it increases to 14 L/h (Roychowdhury and
Talpaz 2011).
The superiority of Imatinib against IFNα was confirmed in the third phase of the International
Randomized Study of Interferon and STI-571 (IRIS). A substantial cytogenetic response was
achieved in 87% of the patients receiving Imatinib after 18 months, compared to 35% in those
who received IFN. Complete cytogenetic remission was observed in 76.2% of the patients
treated with Imatinib, compared to 14.5% of the treated with IFN. Molecular remission with
reduction of the Bcr-Abl transcripts was found in 39% of the patients treated with Imatinib,
against 2% for IFN. 325 (71%) of 456 patients who had achieved complete cytogenetic remission
with Imatinib sustained their remission on the sixth year of treatment. Tracking patients over
the 6-year exploration period indicated that Imatinib had a favourable and long-lasting safety
profile, as there were no new adverse events during the 5th and 6th year of study. The use of
Imatinib as first-line drug for CML did not affect subsequent treatment of patients with
allogeneic hematopoietic stem cells transplantation (Kantarjian, O'Brien et al. 2003; Deininger
2008; Baccarani and Dreyling 2009).
Figure 4. Mode of action of Imatinib. Imatinib blocks the ATP binding center of Bcr-Abl thus inhibiting its phosphory‐
lation activity.
2.2. Second generation tyrosine-kinase inhibitors
2.2.1. Nilotinib
Nilotinib is a highly selective ABL inhibitor and derivative of Imatinib and can overcome some
mutations that can cause imatinib resistance with the exception of T315I. During first phase
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clinical trial, Nilotinib was tested at doses of 50 mg once daily to 600 mg twice daily in 119
Imatinib-resistant CML patients at various stages of the disease. 92% of the patients in chronic
phase achieved complete hematologic remission. 72% of the patients in the acute phase of CML
presented hematologic remission and 48% of them had a cytogenetic response. 39% of patients
with CML in blast crisis demonstrated a hematologic response and 9 of them (27%) had a
cytogenetic response. The results of the study defined a recommended dose of 400 mg twice
daily (Table 1). Nilotinib adverse reactions include small pleural or pericardial effusions. The
most common adverse effects during the study were thrombocytopenia (20% -33%), neutro‐
penia (13% -31%), elevated bilirubin (7%), and increased serum lipase (5% -15%). Grapefruit
and other food that inhibits hepatic metabolism (mainly CYP3A4 inhibitors) should be
avoided. Nilotinib is not recommended for patients with prolonged QT-segment, and drugs
that prolong the QT-segment should not be given during treatment with Nilotinib (Kantarjian,
Giles et al. 2007; Olivieri and Manzione 2007; Weisberg, Catley et al. 2007; Melo and Chuah
2008; Giles, Rosti et al. 2010; Kantarjian, Cortes et al. 2010; Kantarjian, Giles et al. 2010; Quintas-
Cardama, Kim et al. 2010).
2.2.2. Dasatinib
Dasatinib is another ABL kinase inhibitor that binds to the active conformation of the ABL-
kinase domain and to the structurally related kinases of the Src-family. In-vitro dasatinib is 300
times more potent than imatinib against Bcr-Abl mutated blasts. Dasatinib inhibited almost all
Imatinib-resistant Bcr-Abl mutants with the exception of T315I and was shown to block PDGFRs
and KIT. After successful phase II clinical trials dasatinib was approved in North America and
Europe and in many other countries. It should be given to patients with imatinib resistance. During
the trials some severe hematologic adverse effects were observed in imatinib resistant or imatinib
intolerant patients with CML, e.g. thrombocytopenia (48%), anemia (22%), neutropenia (49%),
and leukopenia (27%). There were some non-haematological adverse reactions as well, e.g. pleural
effusions (6%). In the phase III trials, in order to reduce Dasatinib-related toxicity while maintain‐
ing efficacy of treatment, 670 randomly selected imatinib resistant or imatinib intolerant pa‐
tients with CML in the chronic phase received dasatinib in 1 of 4 dose regimens: 100 mg once daily,
50 mg twice daily, 140 mg once daily, or 70 mg twice daily. It was found that non-hematological
and hematological adverse reactions are rarer at a dose of 100 mg once daily (Hochhaus, Kantar‐
jian et al. 2007). Currently, this is the recommended dosage for patients with chronic phase CML,
while the 70 mg twice daily or 140 mg once daily regimens are options for patients in the acute
phase or blast crisis CML (Table 1).
Nowadays, the choice between treatment with dasatinib and nilotinib in imatinib resistant
patients is made on the basis of the history of comorbidities, since no such very important
comparative study of both drugs has been made so far. Therefore, patients with a history of
lung disease may be more suitable for treatment with nilotinib, while patients with pancreatic
disease could benefit from treatment with dasatinib. Patients bearing the T315I mutation are
resistant to treatment with both dasatinib and nilotinib. Such patients should be offered the
option for inclusion in clinical trials or allogeneic bone marrow transplantation (Kantarjian,
Cortes et al. 2010).
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1. Chronic phase of CML:
a Initial therapy:
Imatinib 400 mg p.o. Daily
b Salvage therapy:
Dasatinib 70 mg
100 mg
b.i.d.p.o.
р.о.
Daily
Nilotinib 400 mg b.i.d.p.o. Daily
Imatinib (high-dose) 400 mg b.i.d.p.o. Daily
2. Accelerated phase and blast crisis of CML:
Imatinib 400-600 mg p.o. Daily
Dasatinib 70 mg b.i.d.p.o. Daily
Nilotinib 400 mg b.i.d.p.o. Daily
3. Pediatric patients with CML:
Imatinib 260 mg/m2/d
340 mg/m2/d
p.o
p.o..
daily
daily
Table 1. Treatment schedule with tyrosine kinase-inhibitors.
2.3. Resistance towards TKI — Mechanisms and management
The most important problem in the target therapy of CML today is the development of
resistance towards TKIs. Lucas et al. reported after a population-based study in Northern
England that about 50% of the patients treated with imatinib developed intolerance or failure
up to two years after initiation (Lucas, Wang et al. 2008). Responses obtained in patients with
advanced desease were also not durable. CCyR at 6 years after initiating imatinib therapy is
determined by 57% patients and 55% remain on the treatment after 8 years (Burke, Swords et
al. 2011). Even nilotinib at best achieved CCyR in 80% of the treated patients (Rosti, Palandri
et al. 2009). In summary, there is a significant minority of patients developing resistance
towards imatinib and second generation TKIs. Investigators distinguish between primary and
secondary resistance. Secondary treament failure or desease replase is characterized by the
loss of already achieved complete cytogenetic or hematological response and is dependent on
different factors such as age, stage of disease, duration of INF therapy and duration of response
to initial therapy. In contrast, primary resistance is the failure to achieve CCyR or hematologic
response and is not very well investigated and understood. Concernig leukemic cell prolifer‐
ation and survival two other models of imatinib resintance could be outlined: on one hand
leukemic cells became independent from the fusion oncoprotein for their survuval and
proliferation and, on the other hand the tyrosine kinase Bcr-Abl circuvented the inhibition by
imatinib or other TKIs, e.g. appearance of the mutation T315I (Burke, Swords et al. 2011;
Roychowdhury and Talpaz 2011).
The mechanisms of imatinib resistance could be classified as either Bcr-Abl dependent or Bcr-
Abl independent. Bcr-Abl dependent mechnisms include Bcr-Abl amplification, kinase
domain mutations and Bcr-Abl induced genomic instability. Bcr-Abl independent mechanisms
are usually related to drug complience and metabolism, drug transport, clonal evolution,
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escape of the primitive progenitors from therapy and activation of alternative signal trans‐
duction pathways.
Kinase domain mutations belong to the most important mechanisms of resistance towards
TKIs. They were identified in clinical studies with patients with imatinib resistance (initial or
developed during the therapy) where 30% of the patients had primary resistance and 57% -
secondary resistance (Shah, Nicoll et al. 2002; Soverini, Martinelli et al. 2005). Today over a 90
mutations in the Bcr-Abl fusion gene are described and they affect 57% of the amino-acid
residues. Some of these mutations cause a direct steric interference to drug-enzyme binding
or alter allosterically the kinase domain activity and are reported to be the main reason for
treatment failure in many clinical trials. Mutations in the P-loop are assigned as poor prognistic
factor. In particular, the T315I mutation accounts for the majority of secondary resistance
(Burke, Swords et al. 2011). The T315I mutation is a single amino-acid substitution of isoleucine
with threonine at position 315 on c-Abl. It alters the ATP-binding site of the tyrosine kinase,
confers cross-resistance to nearly all clinically applied TKIs and correlates with decreased
cytogenetic response and progression free survival rates. In summary, in clinical studies about
50% incidence of this mutation had been reported for patients with secondary resistance.
Therefore, introduction of new drugs is substantially needed (Bradeen, Eide et al. 2006).
However, there are studies reporting that kinase domain mutations were found also in patients
with CCyR and in remission, but only few of them eventually developed disease relapse. It is
evident that not all kinds of resistance are due to Abl-mutations and not all mutaions could
lead to resistance (Branford, Melo et al. 2009; Roychowdhury and Talpaz 2011). Correlations
based on in vitro sensitivity have not been consistent in all studies. Thus Bcr-Abl induced
genimic instability or unknown Bcr-Abl independent mechanisms are suspected to be also
responsible for disease resistance development.
In vitro studies showed that Bcr-Abl could promote genomic instability and resistance. There
are additional facts that support the hypothesis that Bcr-Abl can affect the mismatch repair
activity. The fusion protein caused down-regulation of nucleotide excision repair in leukemic
cell lines and promoted double-stranded DNA breaks through single strand annealing
(Stoklosa, Poplawski et al. 2008; Fernandes, Reddy et al. 2009).
Pharmacokinetic characteristics of the TKIs were also demonstrated to be important for better
clinical outcomes. Imatinib is substrate for the liver enzyme CYP3A4 which converts it into
active metabolite. A higher enzyme acitivity correlated with higher rate of complete molecular
responses (Green, Skoglund et al. 2010). The α-1-acid glycoprotein directly binds imatinib, thus
increasing its clearance. Therefore, patients with high levels of this protein demonstrated lower
plasma concentrations of imatinib which worsened the therapeutic response (Delbaldo,
Chatelut et al. 2006). Through in vitro experiments with radio-labeled imatinib it was demon‐
strated that cellular mechanisms for drug transport (influx and efflux) are also important
determinants of the drug sensitivity. The imatinib influx is an active process which involves
the human organic cation transporter 1 (hOCT1). In a study with 56 patients it was reported
that high activity of hOCT1 is associated with significantly improved overall survival and
response rates (Giles, Kantarjian et al. 1999; Roychowdhury and Talpaz 2011). The P-glyco‐
protein (MDR1 or ABCB1) which is responsible for the drug efflux out of the leukemic cells
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also mediated resistance but did not appear to be essential for the development of imatinib
resistance even in primitive CD34+ CML progenitors in vitro.
Another reason for developing resistance towards targeted CML therapy is provided by the
stem cell hypothesis. According to some investigators there is a reservoir of primitive pro‐
genitors that are capable of self-renewal or progression in vitro or in vivo in immunodeficient
mice. Another proof for this hypothesis is the fact that patients with deep remissions in the
chronic phase of CML can relapse after discontinuation of imatinib therapy. There are different
biological mechanisms responsible for the behavior of the stem cell compartment. The Wnt/ß-
catenin signal pathway and the Foxo transcription factors were found to be involved in the
renewal of malignant and normal haematopoietic stem cells. Additionally, the Hedgehog
signaling pathway seems to be important for CML stem renewal. Thus far, it is clear that CML
biology involves a stem cell component, but its exact role and biological mechanisms have not
yet been determined.
The strategies to overcome resistance include first optimization of the front line therapy with
imatinib such as escalation of the daily dose up to 800 mg and second the introduction of second
generation TKIs such as dasatinib, nilotinib (Table 1) and other new compounds that are still
in clinical trials (Jabbour, Kantarjian et al. 2009; Roychowdhury and Talpaz 2011). Dasatinib
and nilotinib were successfully used in patients in accelerated phase or blast crisis after Bcr-
Abl mutation analysis that demonstrated other mutations than T315I. Ponatinib, a new
multiple kinase inhibitor, showed high activity against T315I mutants in vitro and low toxicity
in vivo during a Phase I clinical trial and is a very promising new TKI for the treatment of
patients bearing the T315I mutation. There have been no randomized studies to evaluate the
predictive value of kinase domain mutations for response to specific TKIs until now. However,
a summary of the data can be taken from retrospective studies. Dasatinib is recommended for
patients with the following mutations: Y253H, E255K/V and F359V/C. Nilotinib is beneficial
for pytients with F317L and V299L mutations. The side effect profile and patient’s character‐
istics are also important for the choice of an appropriate TKI (Hughes, Saglio et al. 2009;
Jabbour, Jones et al. 2009; Roychowdhury and Talpaz 2011).
After failure of imatinib and a second generation TKI, most patients could be included in
ongoing clinical trials. Next, some of the novel agents beeing evaluated in Ph(+) leukemias are
listed.
3. Experimental drugs for CML therapy
3.1. Tyrosine kinase inhibitors
3.1.1. Bosutinib
Bosutinib was developed to overcome the resistance to first and second generation TKIs and
is still in clinical trials. It was shown to possess a high antiproliferative activity in vitro and in
xenografts against most of the Bcr-Abl mutants except T315I. It is a dual Abl and Src kinase
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inhibitor and binds to both active and intermediate conformations of the fusion oncoprotein
Bcr-Abl. Bosutinib was found to inhibit the proliferation of CML progenitors about 200 times
better than imatinib. However, it was not able to eliminate all mutant populations and was
moderately effective in inducing apoptosis. The Phase II studies with bosutinib showed that
about 36% of all patients in chronic pahse, 22% in accelerated pahse and 9% in blast crisis
achieved complete cytogenetic responses. Preliminary data indicate that bosutinib was well
tolerated and the most common adverse events were gastrointestinal discomfort and grade
3-4 myelosuppression which occurred in the advanced disease phases (Melo and Chuah
2008; Roychowdhury and Talpaz 2011).
3.1.2. Other experimental tyrosine kinase inhibitors
There are also new types of compounds inhibiting pathobiochemical pathways, resulting from
the bcr-abl oncogene. These allosteric inhibitors use a newly described allosteric, non-ATP
competitive mechanism, potentially involving binding to the myristate pocket in the C-lobe
of the Bcr-Abl kinase domain. The most promising of these compounds is the GNF-2. It has
practically no activity against most kinases, including Kit, PDGFR and SFK. GNF-2 inhibited
the growth of cells with the Y253F and E255V mutations, but not the other P-loop mutants, the
T315I or F317L mutants. Another promising new agent is INNO-406 (Bafetinib) which is Abl/
Lyn kinase inhibitor and is about 55 times more potent than imatinib in vitro. It has been shown
to inhibit numerous Bcr-Abl muitants except T315I. The drug underwent a Phase I study in
patients with resistance to imatinib. It was well tolerated and 2 of 7 patients achieved complete
cytogenetic response. The novel multiple kinase inhibitor, the purine derivate AP24534
(ponatinib) inhibits FLT3, Src kinases, Bcr-Abl and multipule Bcr-Abl mutants, including the
T315I mutation. During the preclinical studies it was evidenced that ponatinib is highly
effective mutant Bcr-Abl inhibitor in vitro and in vivo in mouse models. Interestingly, no dose-
limiting toxicity was found in a dose-escalating Phase I clinical trial. Ponatinib was effective
in patients who had failed to respond to all other approved theprapies, including patients with
the T315I mutation of the fusion oncoprotein Bcr-Abl. Therefore ponatinib is fastly moving to
phase II studies in patients with Ph+ leukemias.
Other new TKIs are the SFK/Abl kinase inhibitor, the anilino-quinazoline AZD0530; the purine
derivates AP23464 and its analogue AP23848; the pyrido-pyrimidines, PDI66326, PDI73955
and PDI180970; thje pyrazolo-pyrimidines, PP1 and PP2; the acetylanes AC22 and K1P. These
compounds have not been developed for clinical use yet (Melo and Chuah 2008; Bixby and
Talpaz 2009; Burke, Swords et al. 2011).
3.2. Aurora kinase inhibitors
The Aurora kinase familiy consists of serine-threonine kinases that are crucial for different
stages of the mitosis. There are two family members Aurira A and B and are overexpressed in
some neoplasias. Following Aurora kinase inhibitors are in pre-clinical and clinical evaluation:
PHA-739358 (danusertib), AT9283, MLN8237XL-228, KW-2449 and MK-0457. Danusetib
showed safety profile and efficacy in patients bearing the T315I mutation in phase I clinical
study. AT9238 is a multi-kinase inhibitor which also inhibited cells with the T315I mutation.
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It was well-tolerated during phase I clinical trial and shwed promising anti-leukemic activity
(Cortes-Franco, Dombret et al. 2009; Howard, Berdini et al. 2009; Moore, Blagg et al. 2010;
Tanaka, Squires et al. 2010; Burke, Swords et al. 2011).
3.3. Heat shock protein 90 inhibitor
As a molecular chaperone that interacts with various proteins (Raf, Akt, FLT-3 and Bcr-Abl)
Hsp90 maintains those proteins in a stable and functional conformation. Geldanamycin and
its derivative, 17-allylamino-17-demethoxygeldanamycin (17-AAG) bind to the ATP-binding
pocket of Hsp90 and inhibit its chaperone activity. This leads to downregulation of Bcr-Abl
and also induction of apoptosis in CML cell lines. Gledanamycin and 17-AAG inhibited the
cell growth of some mutant lines (E255K and T315I). Hsp90 has its limits and there are some
cross-resistant types. Combination therapy with imatinib and 17-AAG led to synergistic
inhibition of growth and induction of apoptosis in cross-resistant cell lines but not in the
imatinib-sensitive counterparts. 17-AAG may also block the imatinib efflux (Melo and Chuah
2008; Burke, Swords et al. 2011).
3.4. Arsenic trioxide
Another compound that induces apoptosis in Bcr-Abl-positive cell lines and reduces prolifer‐
ation of CML blasts without affecting the CD34+ progenitors, is the arsenic trioxide (As2O3).
The combination of As2O3 with imatinib exerted additive to synergistic effect. This combination
induced cell death in imatinib-resistant cell lines with overexpressed Bcr-Abl or bearing M351T
or Y253F mutations, but it does not affect the T315I mutants (Melo and Chuah 2008; Roy‐
chowdhury and Talpaz 2011).
3.5. Homoharringtonine
Homoharringtonine (HHT), a by-product of a plant alkaloid, inhibits protein synthesis and
induces apoptosis. The combination of HHT with imatinib is synergistic or additive on CML
derived cell lines. Omacetaxine and chemgenex are semisynthetic HHT derivatives that
combined with imatinib showed promising activities. Omacetaxine is now in phase II trials
with TKIs-resistant patients with or without the T315I mutation (Melo and Chuah 2008; Burke,
Swords et al. 2011).
3.6. Histone deacetylase inhibitors
Histone deacetylases (HDAC) are the catalysts in deacetylation of lysine residues at the amino
termini of core nucleosomal histones. Histone deacetylase inhibitors (HDI) such as suberoy‐
lanilide hydroxamic acid (SAHA, vorinostat), generate hyperacetylated histones, causing
transcriptional upregulation of the cyclin-dependent kinase inhibitor, p21, cell-cycle arrest and
apoptosis in tumor cells. SAHA also induces expression of a key cell-cycle regulator p27, and
its application is associated with downregulation of the p210 Bcr-Abl protein. There is a
synergetic interaction between SAHA and imatinib on CML cell lines. The mentioned combi‐
nation induces apoptosis in imatinib-resistant CML cell lines as well. The co-treatment with
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nilotinib and the HDI LBH589 (panobinostat) was very effective in inducing apoptosis in K-562
and LAMA-84 CML cell lines. LBH589 showed efficacy in imatinib-resistant cell lines bearing
the T315I and E255K mutations and this was associated with depletion of Bcr-Abl. A published
study showed that when combined with imatinib, the HDI valproate can increase the antileu‐
kemic efficacy and sensitize imatinib-resistant CML cells (Kantarjian, O'Brien et al. 2003; Melo
and Chuah 2008; Burke, Swords et al. 2011).
3.7. Proteasome inhibitors
Proteasomes are responsible for the degradation of different cellular proteins. The proteasome
inhibitor bortezomib was shown to inhibit proliferation, to stop the cell cycle in the G2/M phase
and to promote apoptosis in imatinib-sensitive and imatinib-resistant CML cell lines. Co-
treatment with bortezomib and imatinib isn’t recommended because there are some antago‐
nistic interactions. However, if a low dose bortezomib exposure of CML cell lines is followed
by imatinib, there are some additive effects. Synergistic interactions between bortezomib and
the HDI SAHA are reported, and between bortezomib and flavopiridol in in vitro as well (Melo
and Chuah 2008).
3.8. Semi-synthetic drugs
Semi-synthetic drugs flavone and flavopiridol are going through clinical trials. They target
multiple cyclin-dependent kinases. Flavopiridol showed a very promising activity in combi‐
nation with imatinib for inducing apoptosis in Bcr-Abl-positive CML cell lines (Melo and
Chuah 2008).
3.9. Farnesyl Transferase Inhibitors (FTIs)
Current FTIs under investigation and with a potential as antileukemic agents are tipifarnib
and lonafarnib. They are inhibitors of the Ras-MAPK signal pathway which was shown to
couple to Bcr.Abl through protein-protein interactions and to play a central role in leukemo‐
genic transformation. Tipifarnib is in Phase II trial involving 22 patients with CML. Complete
or partial hematological response was achieved in 32% of the patients. The combination
imatinib and tipifarnib was well tolerated and active in patients with imatinib-resistnat CML
– a partial cytogenetic response was achieved in patients harboring the T315I mutant. Lona‐
farnib is a selective inhibitor of primary progenitor cells derived from CML patients. It reduced
colony formation of progenitor cells and showed activity in imatinib-resitant CML cell lines.
However, the reports from a pilot study demonstrated that only 2 of 13 patients achieved a
clinical response.
3.10. Raf-1 inhibitors
Sorafenib (BAY 43-9006) is a multi kinase inhibitor of the RAS/Raf pathway which is involved
in leukemogenesis downstream from Bcr-Abl. Drug concetrations of 5-10 µM were found to
induce apoptosis via the mitochondrial pathway in imatinib-rsistant cell lines. The combina‐
tion between sorafenib and vorinostat (HDAC inhibitor) triggers cell dysfunction through
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Mcl-1 downregulation and p21 inhibition. Sorafenib is approved for the treatment of hepato‐
cellular and renal cancers and Phase I and Phase II trials are carried out in CML patients (Burke,
Swords et al. 2011).
3.11. MEK inhibitors
CI-1040 was the first MEK inhibitor which entered a clinical trial in CML patients. It has been
studied in combinations with imatinib, dasatinib, HDAC inhibitors, arsenic trioxide and HSP
90 inhibitors. The last two combinations were tested with a positive effect in patients with
T315I mutation. Because of the challenging pharamokinetic properties, clinical advancement
is unlikely, but a derivate (PD0325901) is under development (Burke, Swords et al. 2011).
3.12. mTOR inhibitors
The protein kinase, mTOR (mammalian target of rapamycin), is a downstream mediator in the
PI3K/Akt pathway which controls cell growth and survival. Rapamycin (sirolimus) is the
prototype compound of this group, but it has poor aqueous solubility and chemical stability,
limiting its clinical usefulness. However, in a small clinical trial four out of six patients with
imatinib-resistant disease responded to oral rapamycin. Rapamycin also significantly inhibit‐
ed the cell growth in Ph+ cell lines with or without the T315I mutation. The combination
between imatinib and another mTOR inhibitor, everolimus, was associated with an increased
expression of c-Abl and inhibition of Bcr-Abl. In the presence of inhibited Bcr-Abl, c-Abl enetrs
the nucleus an modulates apoptosis. A Phase I trial with imatinib and everolimus has been
completed while a study with temsirolimus is currently in accrual (Burke, Swords et al. 2011).
4. Interferons
Before the era of TKIs and since the 1980s interferon-α had constituted the first-line therapy
for CML patients in the chronic phase of the disease. Interferon induced long-lasting remis‐
sions in up to 80% of the patients with complete cytogenetic response. After interferon therapy
they had disease-free survival beyond 10 years. There are some clinical trials that showed
succesful combinations between TKIs and interferon which provided an adjunct immunologic
response during induction or maintenance therapies. Treatment with interferon after imatinib
was shown to be followed by a possible remission status (Burchert, Muller et al. 2010;
Roychowdhury and Talpaz 2011). Howerver, additional data are required in order to clarify
the role of interferon in conjunction to the TKI therapy.
5. Stem cell transplantation
Allogeneic stem cell transplantation (ASCT) was first line therapy for CML patients for many
years. In the imatinib era, however, ASCT is becomning second or even third option for these
patients if hematological, cytogenetic or molecular remission with imatinib is not achieved
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after 3,12 and 18 months, respectively (Baccarani and Dreyling 2009). ASCT is still the only
treatment that offers a definitive cure. The risks of ASCT are some mortality rate, graft-versus-
host disease (GVHD), potentially lethal acute or chronic infections death and risk of second
malignancy. There are no data about negative influence on ASCT of pre-treatment with
tyrosine-kinase inhibitors. In a single institution in the USA between 1995 and 2000 131 CP
CML patients underwent allogeneic SCT with bone marrow or perpheral blood from related
donors. In the 3 year long period, the probability of disease-free survival was 78%. The survival
and disease recurrence rates were estimated at 86% and 8% respectively. The Chronic Leuke‐
mia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
published own data. In the period between 2000 and 2003 3018 patients were treated with
ASCT for CML. The 2-year survival rate was 61%, the transplant-related mortality rate was
30%, and the rate of disease recurrence was 22%. Better results were observed in patients who
underwent ASCT at the time of first CP using as a donor an HLA-identical sibling. The 2-year
survival rate in this case was 74%, transplant-related mortality rate 22% and disease recurrence
rate 18%. This confirms the fact that the outcome of ASCT is highly dependent on risk factors.
EBMT study showed that favorable factors are sibling donor, treatment at early stage of the
disease, under 12 months after diagnosis, and younger age of the patient (age under 20 years
is better than 20-40 years, and above 40 the risks are higher). If successful, ASCT can lead to
long-lasting results. In a 10-year study of patients transplantated with an allogeneic bone
marrow from siblings, the mean time of hematologic or cytogenetic disease recurrence was 7.7
years and 46% of the long-term survivors never developed disease recurrence.
One of the main problems standing in front of ASCT is that most of the patients don’t have a
suitable HLA-matched sibling. National Marrow Donor Program institutions in the U.S.
conducted a study in the period between 1988 and 1999 that compared results from 2464
unrelated donor bone marrow transplantations with 450 HLA-identical sibling donor trans‐
plantations. The results from this study confirm that patients transplantated with bone marrow
from a non-relative donor have greater risk of complications. However it is important to
mention that data from this study didn’t show a significant difference in the 5-year survival
rate between the two types of donors if the transplantion was made within 1 year after
diagnosis (Jabbour, Cortes et al. 2007).
6. Conclusion
Imatinib is now the most common first line drug for the treatment of CML and is a hallmark
of target drug therapies for malignant diseases. However resistance to this drug is a major
problem that can’t be overcome by increasing the dosage (Jabbour, Kantarjian et al. 2007;
O'Hare, Eide et al. 2007). Single agent therapy with imatinib may not be the best long-term
option in many of the CML patients and other approaches should be considered. There are
many novel compounds that are in development and in preclincal and clinical trials, some of
them showed very promising results. Dasatinib, nilotinib and bosutinib are representatives of
the newer generation TKIs which are effective and safe to use in imatinib-resistant and/or -
intolerant CML patients. It is very likely that new Bcr-Abl mutants will become resistant to
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these small-molecule inhibitors. Therefore, other therapeutic approaches are required. The
combination of TKIs with other inhibitors of non-Bcr-Abl targets is needed to overcome the
resistance.
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